Codes and Coverage

Supporting patient access

BMS Access Support^® may help support patient access by conducting benefits reviews and offering prior authorization and appeals process assistance for enrolled patients. Additionally, the information below provides product-specific billing and diagnosis codes, reimbursement and coding guides, distribution information, and additional coverage support offerings. To view available coding and coverage information, please select your patient’s prescribed medication.

Additional eligibility criteria and terms may apply. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Benefits Reviews

Once a patient is enrolled in BMS Access Support, we can review their insurance coverage
A benefits review may help determine whether or not a medication is covered, if a PA is required, and estimated patient out-of-pocket costs

Prior Authorization (PA) and Appeals Assistance

Use the BMS Access Map to identify plan-specific PA requirements
View our forms and resources page for helpful support tools, including appeals letter templates and medical necessity letters

Annual Reverification

Reverification of benefits is available upon request to confirm a patient’s benefits for the new year
Connect with your local Access and Reimbursement Manager for more information

ZENBEXUS^TM

(iberdomide)

Indication(s)

Important Safety Information

U.S. Full Prescribing Information, including Boxed WARNINGS

ZENBEXUS is only available through ZENBEXUS REMS.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Reimbursement and Coding Guide for ZENBEXUS

Additional coverage support offerings

Free Trial Offer

A free trial offer may be available for patients newly prescribed ZENBEXUS.

Bridge Program

Has your commercially insured patient experienced a delay in coverage or a coverage denial for ZENBEXUS? They may be eligible for a bridge program while they await coverage.

To learn more about the eligibility requirements for the Free Trial offer or Bridge Program, call BMS Access Support at 1-800-861-0048 or reach out to your local Access and Reimbursement Manager for more information.

Restrictions apply. Please see full Terms & Conditions, including complete eligibility requirements.

Explore codes on this page: ⬇NDC ⬇CPT

National Drug Codes (NDC)¹

Issued by the FDA

Note: Payers require the submission of the 10-digit NDC on healthcare claim forms. Please use the 10-digit codes shown here.

0003-5700-21	0.75 mg capsules, bottle of 21 capsules
0003-5710-21	1 mg capsules, bottle of 21 capsules

International Classification of Diseases, Tenth Revision, Clinical Modification Diagnosis Codes (ICD-10-CM)²

Multiple Myeloma ICD-10 Codes

C90	Multiple myeloma and malignant plasma cell neoplasms
C90.0	Multiple myeloma
C90.00	Multiple myeloma not having achieved remission
C90.01	Multiple myeloma in remission
C90.02	Multiple myeloma in relapse

Coding for ZENBEXUS is dependent on the insurer and the care setting in which the drug will be administered. Oncology practices need to make coding decisions based on the diagnosis and treatment of each patient and the specific insurer requirements.

Please see U.S. Full Prescribing Information for ZENBEXUS, including Boxed WARNINGS.

The HCP and patient are responsible for the accurate completion of documents regarding reimbursement or coverage. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item. This is not a comprehensive list of ICD-10-CM codes.

*Healthcare providers should code healthcare claims based upon the service that is rendered, the patient's medical record, the coding requirements of each health insurer, and best coding practices. Coding information provided under this heading does not provide a guarantee of reimbursement and should be considered together with all applicable coding guidance and standards. All of the coding information presented by this website is applicable to outpatient procedures only.

References:

ZENBEXUS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
Centers for Medicare & Medicaid Services. 2026 ICD-10-CM tabular list of diseases and injuries. https://www.cms.gov/files/zip/2026-code-tables-tabular-and-index.zip. Accessed March 2, 2026.

ZENBEXUS (iberdomide) is available through a limited REMS-Pharmacy Network that includes specialty pharmacy dispensing and in-office dispensing community practices and hospitals that are contracted to fill prescriptions for restricted distribution programs for Bristol Myers Squibb. Prescribers and pharmacies must be certified with the CELMoD REMS program by enrolling and complying with the REMS requirements; pharmacies must only dispense to patients who are authorized to receive ZENBEXUS.

To support both patient and provider choice, all Specialty Pharmacies within the Limited Dispensing Network are authorized to dispense ZENBEXUS. ZENBEXUS must not be subject to any restrictions that limit fulfillment to one specific Specialty Pharmacy.  Participating pharmacies have agreed not to impose restrictions on dispensing through a particular pharmacy or prohibit patient fulfillment through any Network pharmacy.  If there are concerns that patient or provider choice is not being maintained in practice, please send notice to BMS at BMS_PharmacySupport@bms.com.

Pharmacy

Authorized Distributor	Phone & Fax Orders
AcariaHealth, Inc.	Phone: 1-866-458-9246 Fax: 1-866-458-9245
Accredo Health Group, Inc.	Phone: 1‑877-732-3431 Fax: 1‑800-590-1021
Amber Enterprises, Inc.	Phone: 1-888-370-1724 Fax: 1-877-645-7514
Ardon	Phone: 1-855-425-4085 Fax: 1-855-452-4096
Biologics, Inc.	Phone: 1-800-850-4306 Fax:1-800-823-4506
BioMatrix Specialty Pharmacy, LLC	Phone: 1-855-359-9679 Fax: 1-610-545-6030
BioPlus Specialty Pharmacy, LLC	Phone: 1-888-292-0744 Fax:1-800-269-5493
Birdi	Phone: 1-877-437-9012 Fax:1-877-309-0687
Caremark, L.L.C.	Phone: 1-800-237-2767 Fax:1-800-323-2445
CenterWell	Phone: 1-800-486-2668 Fax:1-877-405-7940
CoverMyMeds Pharmacy (VA Dispensing)	Phone: 1-855-637-9433 Fax:1-855-637-9446
Lumicera	Phone: 1-855-847-3553 Fax:1-855-847-3558
Meijer	Phone: 1-855-263-4537 Fax:1-734-391-2365
OncoMed Specialty, LLC dba Onco360	Phone: 1-877-662-6633 Fax:1-877-662-6355
Optum Pharmacy, LLC	Phone: 1-877-445-6874 Fax:1-877-342-4596
Polaris	Phone: 1-855-797-0857 Fax:1-800-781-3364
Prime Therapeutics Pharmacy, LLC	Phone: 1-866-554-2673 Fax:1-866-364-2673
Publix	Phone: 1-855-797-8254 Fax:1-863-413-5723
Senderra	Phone: 1-877-513-3107 Fax:1-855-662-6779
SortPak	Phone: 1-877-570-7787 Fax:1-877-475-2382
Upstate Pharmacy LTC	Phone: 1-800-314-465 Fax:1-800-314-7756
Walgreens Specialty Pharmacy	Phone: 1-800-516-9180 Fax:1-877-231-8302
Walmart Specialty Pharmacy	Phone: 1-877-453-4566 Fax:1-866-537-0877

Puerto Rico

Authorized Distributor	Phone & Fax Orders
Absolute Pharmacy, Inc.	Phone: 1-787-892-8700 Fax: 1-787-264-5800
Alivia	Phone: 1-787-925-1989 ext. 8191 Fax: 1-787-925-1015
CVS Specialty	Phone: 1-787-759-4162 Fax: 1-855-297-1270
Farmacia Doral, Inc, a BioPlus company	Phone: 1-844-355-4191 Fax: 1-800-546-2163
Farmacia San Rafael Santurce, Inc.	Phone: 1-787-724-3333 Fax: 1-787-721-4165, 1-787-721-3399
MedPlus	Phone: 1-787-523-3888 Fax: 1-787-777-1580
Special Care Pharmacy Services, LLC	Phone: 1-787-781-4585 Fax: 1-787-783-2951
SPS	Phone: 1-787-704-2025 Fax: 1-787-704-2027
Walgreens Specialty Pharmacy	Phone: 1-787-777-1120 Fax: 1-787-777-1124, 1-787-758-3730

Above information is accurate as of 08/26.

The ZENBEXUS distribution program includes extended payment terms to Bristol Myers Squibb authorized ZENBEXUS distributors. Healthcare providers and institutions should contact their ZENBEXUS distributor to understand specific payment terms that may be available to them from their distributor.

Please see U.S. Full Prescribing Information for ZENBEXUS, including Boxed WARNINGS.

FDA Approval Letters as Posted by the FDA:

In combination with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy.

This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.

View Letter